After reaching unprecedented highs in 2021, global M&A markets had a bumpy ride in 2022 as dealmakers grappled with inflation, rising interest rates and fallout from the conflict in Ukraine.
Deal value for 2022 came in...more
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more
1/30/2023
/ Acquisitions ,
Buyers ,
Capital Markets ,
CFIUS ,
Coronavirus/COVID-19 ,
Cryptocurrency ,
Department of Justice (DOJ) ,
Domestic Dealmaking ,
Environmental Social & Governance (ESG) ,
EU ,
Federal Trade Commission (FTC) ,
Financial Institutions ,
Financial Services Industry ,
Global Dealmaking ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Publicly-Traded Companies ,
Real Estate Market ,
Securities and Exchange Commission (SEC) ,
Sellers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
Explore the data The headline for the first half of 2022 is that US M&A markets are still remarkably healthy, despite a confluence of headwinds. Without question, 2021 was an exceptional year, fueled by pent-up demand,...more
8/23/2022
/ Acquisitions ,
Capital Markets ,
Deal Price ,
Domestic Dealmaking ,
EBITDA ,
Environmental Social & Governance (ESG) ,
Fair Market Value ,
Global Dealmaking ,
Greenwashing ,
Market Price ,
Mergers ,
Popular ,
Private Equity ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)
Five factors that will shape dealmaking over the coming 12 months -
Last year will be a very tough act to follow. M&A values and volumes soared on the back of confident public markets, strong deal financing options and a...more
2/7/2022
/ Acquisitions ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Federal Trade Commission (FTC) ,
Interest Rates ,
Mergers ,
Private Equity ,
Regulatory Oversight ,
Securities and Exchange Commission (SEC) ,
Special Purpose Acquisition Companies (SPACs) ,
Stock Markets
Global dealmaking was consistently strong in 2021, with the value topping US$1 trillion in each quarter for the first time on record. This achievement is particularly impressive given the tumultuous deal environment, as M&A...more
Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking-
Dealmaking within the pharma, medical and biotech sector continued from...more
12/21/2021
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Medical Research ,
Mergers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
Despite a drop on the previous quarter, Q3 2021 global M&A value represented the strongest Q3 on Mergermarket record -
The third quarter is usually a sleepy one for M&A—but not so this year. A total of US$1.4 trillion in...more
After a turbulent 18 months which saw M&A crash before an impressive return to form, H2 2021 is set for continued strong deal activity, as well as new challenges -
US M&A progressed steadily through the first half of 2021....more
8/10/2021
/ Acquisitions ,
Biden Administration ,
CFIUS ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Enforcement ,
Global Dealmaking ,
Investment ,
Liquidity ,
Mergers ,
National Security ,
Securities and Exchange Commission (SEC) ,
Special Purpose Acquisition Companies (SPACs) ,
Stock Markets ,
Technology Sector ,
Vaccinations
Healthy deal activity has returned to the leisure and retail sectors—areas of the economy that were among the worst affected by the pandemic.
Together, the leisure and retail sectors saw M&A value reach US$41.7 billion...more
Dealmaking within the PMB sector enjoyed an impressive start as companies across the globe embarked on their post-pandemic recovery -
The global pharma, medical and biotech (PMB) sector saw US$95.4 billion in deal...more